医学
骨质疏松症
重症监护医学
肾
肾移植
肾脏疾病
心理干预
内科学
梅德林
肾移植
疾病
作者
Aschariya Wipattanakitcharoen,Tanun Ngamvichchukorn,Sirinatta Prachathai,Kullaya Takkavatakarn,Kearkiat Praditpornsilpa,Paweena Susantitaphong
出处
期刊:Kidney medicine
[Elsevier BV]
日期:2026-09-17
卷期号:8 (11): 101537-101537
标识
DOI:10.1016/j.xkme.2026.101537
摘要
Rational & Objective: Osteoporosis is a common complication after kidney transplantation and contributes to fracture risk and morbidity among kidney transplant recipients (KTRs). However, the efficacy of pharmacological interventions for osteoporosis in this population remains uncertain. Study Design: Systematic review and meta-analysis. Setting & Participants: KTRs. Selection Criteria for Studies: PubMed, Scopus, and the Cochrane Library were searched through December 2024 for randomized controlled trials evaluating pharmacological treatments' effects on bone turnover markers, bone mineral density (BMD), and fracture incidence in KTRs. Data Extraction: Three independent reviewers extracted study characteristics, type of pharmacological interventions and comparators, and outcomes, including bone turnover markers, BMD, and fracture rates. Analytical Approach: A random-effects model was used to calculate weighted mean differences (WMD) for continuous outcomes and relative risks for categorical outcomes. Results: = 0.05). Limitations: ) because of varied pharmacological agents, initiation timing, and recipient characteristics. Conclusions: Pharmacological interventions for osteoporosis in KTRs significantly improved BMD at several skeletal sites, particularly radius site. However, a nonsignificant trend toward reduced fracture incidence was observed.
科研通智能强力驱动
Strongly Powered by AbleSci AI